CRISPR Breakthrough Upends Sickle Cell

A 23-year-old from Louisiana just rang a bell at his hospital — and for the first time in his life, his blood is working the way it should.

Story Snapshot

Daniel Cressy of Metairie, Louisiana became the first person in the state to receive Casgevy, a CRISPR gene-editing therapy for sickle cell disease.
About 100 days after treatment, doctors confirmed his hemoglobin levels were normal — the highest of his entire life.
Casgevy was approved by the U.S. Food and Drug Administration (FDA) in December 2023 and costs $2 million per dose.
Doctors call it a “functional cure,” meaning it stops the disease from causing harm, though patients still need long-term medical follow-up.

A Disease That Controlled Every Day of His Life

Sickle cell disease is not a quiet condition. It warps red blood cells into rigid crescent shapes that get stuck in blood vessels, cutting off oxygen to organs and causing waves of intense pain called crises. For Daniel Cressy, that was life. Not occasionally — constantly. The disease shaped what he could do, where he could go, and what he could dream about. His goal of becoming a commercial pilot felt out of reach.

What Casgevy Actually Does Inside the Body

Casgevy works by editing a patient’s own stem cells using a gene-editing tool called CRISPR-Cas9. The therapy switches on a gene that produces fetal hemoglobin — a form of hemoglobin the body normally stops making after birth. Fetal hemoglobin does not sickle. By reactivating it, the therapy floods the blood with healthy, flexible cells that carry oxygen the way they should. The FDA approved Casgevy in December 2023 for patients 12 and older who suffer from recurring pain crises.

The process is not easy. Before the edited cells go back in, patients must go through intense chemotherapy to wipe out the existing bone marrow. Cressy lost his hair. His skin changed. He suffered painful mouth sores. The treatment demands a serious physical toll before it delivers its reward. That is a real barrier — not just emotionally, but practically — and it deserves honest discussion alongside the breakthrough headlines.

Three Months Later: Numbers That Tell the Story

Roughly 100 days after his infusion, Cressy’s doctors at Manning Family Children’s Hospital confirmed normal hemoglobin levels and no active sickle cell disease. His hemoglobin was the highest it had ever been in his life. He told the BBC World Service he can now run, walk long distances, and is actively pursuing his dream of becoming a commercial pilot. Those are not small things. For someone who lived under the weight of this disease, they are everything.

What “Functionally Cured” Really Means

Doctors are careful with their words here, and that care is worth respecting. They say Cressy is “functionally cured,” not completely cured. The distinction matters. The therapy stops the disease from causing harm. It does not erase the underlying genetic mutation. Patients still need long-term follow-up. Clinical trial data showed most participants stayed free of severe pain crises for at least 12 months — but Cressy is only three months out, so the long-term picture is still being written.

That said, no credible medical voice has stepped forward to dispute his results. His lab numbers are real. His hospital confirmed them. The FDA reviewed the clinical data and approved the therapy. Caution about long-term durability is reasonable science — it is not a reason to dismiss what has already happened in this young man’s body.

The $2 Million Question Nobody Wants to Answer

Here is where the story gets complicated. Casgevy costs $2.2 million per dose — for the drug alone, before hospital fees. Cressy said getting insurance approval was difficult. Fewer than 100 people worldwide have received the treatment. A doctor quoted in the BBC broadcast noted that for most patients in the developing world, this therapy simply does not exist as an option. That is a serious problem. A cure that only reaches a handful of people is a scientific triumph with an unfinished moral chapter.

A Milestone That Points Somewhere Bigger

Gene therapy has been promising cures for decades. What makes this moment different is that the cure is here, confirmed, and walking around in Louisiana talking about flight school. The hard work now is cost, access, and time. Insurers need to cover it. Hospitals need to be equipped to deliver it. And researchers need years of follow-up data to confirm what looks, right now, like a genuine turning point in how medicine treats a disease that has burdened millions of families for generations.